Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CHS-1000

Monoclonal antibody · Antagonist of LILRB2 · developed by Coherus Oncology

Phase 1 Most advanced trial

CHRS Developer

1 Registered trials

What is CHS-1000?

CHS-1000 is a Fc-modified humanized IgG1 monoclonal antibody that binds the inhibitory receptor LILRB2 (ILT4), expressed mainly on myeloid cells and in certain tumors. By blocking binding of its ligands HLA-A and HLA-G, it abrogates LILRB2-mediated immunosuppression in the tumor microenvironment. It is being studied in advanced or metastatic solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Monoclonal antibody
Targets: LILRB2, HLA-A (binding partner it blocks), HLA-G (binding partner it blocks)
Mechanism: Antagonist of LILRB2
Pathways: LILRB2-mediated inhibitory signaling, myeloid cell re-polarization to pro-inflammatory phenotype, dendritic cell and T cell activation, pro-inflammatory cytokine secretion
Therapy area: Oncology
Developer: Coherus Oncology, Inc. (CHRS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06389526	Phase 1	Advanced or Metastatic Solid Tumors	Not yet recruiting	CHRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced or Metastatic Solid Tumors

Other drugs acting on LILRB2

CDX-585 Phase 1 IO-108 Phase 1/2

More from Coherus Oncology

Toripalimab FDA approved Casdozokitug Phase 2 CHS-0214 Phase 3 Perenostobart Phase 2 Tagmokitug Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CHRS page.

Follow CHRS, the company behind CHS-1000

See CHRS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CHRS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z